Clinical trials: Depressive Disorder NOS
Major Depressive Disorder
Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability
Iloperidone is an atypical antipsychotic drug, FDA-approved for the acute treatment of schizophrenia in adults in 2009 (Marino et al., 2010); moreover, some of its pharmacological features seem to be very promising in treating…
- Trial name
- NCT01464229
- Testing
- Iloperidone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Maurizio Fava, MD
Major Depressive Disorder
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD
- Trial name
- NCT01715805
- Testing
- Cariprazine, Antidepressant Therapy (ADT)
- Where
- 85 sites in United States, Puerto Rico
- Volunteers
- 1,022 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
A Study of Fluoxetine in Major Depressive Disorder (MDD) Long-Term Dosing
This study will evaluate the safety and effectiveness of fluoxetine flexible dosing in the treatment of MDD in adult Japanese participants.
- Trial name
- NCT01808651
- Testing
- Fluoxetine
- Where
- 16 sites in Japan
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD
This study will assess the safety, tolerability and efficacy of desvenlafaxine succinate sustained release (DVS SR) in subjects with major depressive disorder.
- Trial name
- NCT00445679
- Testing
- DVS SR, Paroxetine
- Where
- 43 sites in China, India and 2 more
- Volunteers
- 807 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder, Depression
Buprenorphine Used With Treatment Resistant Depression in Older Adults
The investigators are conducting a research study to learn about the safety and benefit of using a medication called buprenorphine for patients with difficult to treat depression.
- Trial name
- IRLGreyB (NCT02181231)
- Testing
- venlafaxine XR, buprenorphine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Obsessive-Compulsive Disorder, Generalized Anxiety Disorder
Improving Attentional and Cognitive Control in the Psychological Treatment of Intrusive Thoughts
The investigators are conducting this study to learn more about the cognitive and attentional processes among individuals with three types of repetitive negative thinking (RNT): mental rituals (as seen in obsessive compulsive…
- Conditions
- Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Major Depressive Disorder
- Trial name
- NCT04225624
- Testing
- Emotion Regulation Therapy - Attention Regulation (AR-ERT), Supportive Psychotherapy (SPT)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Massachusetts General Hospital
Persistent Depressive Disorder
Behavioral Activation (BA) for Medication-responsive Chronically Depressed Patients With Impaired Social Functioning
The investigators aimed to assess the ability of a modified version of Behavioral Activation for occupational and social improvement to produce change in: 1. social adjustment, 2. work functioning, 3. avoidance behavior and 4.
- Trial name
- NCT01783080
- Testing
- Behavioral Activation for return to work
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder.
- Trial name
- RELIANCE-II (NCT04855747)
- Testing
- REL-1017
- Where
- 70 sites in United States
- Volunteers
- 236 people
- Sponsor
- Levomecor Inc.
Depressive Disorder, Major
Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)
The study will evaluate the efficacy, safety, and tolerability of 225 milligrams (mg) and 450 milligrams (mg) of Rapastinel, compared to placebo in participants with major depressive disorder (MDD).
- Trial name
- NCT03675776
- Testing
- Rapastinel
- Where
- 23 sites in Hungary, Japan and 3 more
- Volunteers
- 50 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Major Depressive Disorder
5-HTP and Creatine for Depression
This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression.
- Trial name
- NCT04395183
- Testing
- 5-Hydroxytryptophan 100 MG, Creatine monohydrate
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Utah
Major Depressive Disorder, Post-Traumatic Stress Disorder (PTSD)
PET Imaging of mGLuR5 With Drug Challenge
This study is designed to look at that involvement of a process in the brain called the glutamate system in depression. Participants will undergo a screening session, up to two functional Magnetic Resonance Imaging (fMRI) scans…
- Trial name
- NCT01691092
- Testing
- Ketamine
- Where
- 3 sites in United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Yale University
Treatment Resistant Depression
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
The Safety and Efficacy of Psilocybin as an Adjunctive Therapy in Participants with Treatment-Resistant Depression
- Trial name
- NCT04739865
- Testing
- Psilocybin
- Where
- 2 sites in United States, Ireland
- Volunteers
- 19 people
- Sponsor
- COMPASS Pathways
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01180400
- Testing
- TC-5214
- Where
- 66 sites in Czechia, Estonia and 8 more
- Volunteers
- 295 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder
The purpose of this study was to further characterize the efficacy, safety, and tolerability of a single fixed dose level of vilazodone compared to placebo in patients with major depressive disorder.
- Trial name
- NCT01473394
- Testing
- Vilazodone
- Where
- 14 sites in United States
- Volunteers
- 518 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Magnetic Resonance Imaging Study of Geriatric Depression
The purpose of this study was to use Magnetic Resonance Images to further our understanding of predictors and markers of treatment response and non-response in geriatric depression.
- Trial name
- NCT00245557
- Testing
- Sertraline
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Major Depressive Disorder
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy of an 8-week double-masked treatment of tasimelteon or placebo in male and female subjects with Major Depressive Disorder.
- Trial name
- MAGELLAN (NCT01428661)
- Testing
- tasimelteon
- Where
- 40 sites in United States
- Volunteers
- 507 people
- Sponsor
- Vanda Pharmaceuticals
Depression
Org 24448 to Treat Major Depression
This study will evaluate the effectiveness of the experimental drug, Org 24448, for short-term treatment of depression. It will examine the effects of the drug on symptoms, such as low mood and persistent sadness, poor sleep and…
- Trial name
- NCT00113022
- Testing
- Org 24448
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
rTMS for Depressed Teens: A Sham-Controlled Trial, Part 1
This research proposal aims to better understand the neurobiology of depression in adolescents and how repetitive transcranial magnetic stimulation (rTMS) may therapeutically impact brain function and mood.
- Trial name
- NCT01804270
- Testing
- Repetitive transcranial magnetic stimulation (rTMS)
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Paul E. Croarkin
Major Depressive Disorder, Bipolar Disorder
Wake Therapy in the Treatment of Depression
This pilot study seeks to replicate previous findings that sleep deprivation results in marked improvement in depression symptoms, as well as to test whether concurrent treatment with Light Therapy and Lithium are successful in…
- Trial name
- NCT01431573
- Testing
- Wake Therapy, light box, Lithium
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- New York State Psychiatric Institute
Treatment Resistant Depression
Pilot Accelerated Theta Burst in Treatment-Resistant Bipolar Depression
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant bipolar depression.
- Trial name
- NCT03953417
- Testing
- Accelerated intermittent theta-burst treatment
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Stanford University